Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation (AMS-AF)
Primary Purpose
Atrial Fibrillation
Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions
Conventional general practitioner management model
Sponsored by
About this trial
This is an interventional health services research trial for Atrial Fibrillation focused on measuring Atrial fibrillation, Anticoagulation management plan and process, Primary medical institutions
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years old, regardless of sex.
- It is consistent with the diagnostic basis of atrial fibrillation in "Atrial Fibrillation: current Cognition and treatment recommendations-2018".
- Receive oral anticoagulant therapy, such as warfarin or NOACs, as needed.
- There is a contracted family doctor (if not, they can be included in the study after guiding them to sign up for a family doctor).
- Have certain reading comprehension ability, be able to follow up regularly, have good compliance, and select the residents living in the vicinity.
- Volunteer to participate in this clinical study and sign a written informed consent form
Exclusion Criteria:
- Other diseases requiring anticoagulant therapy, such as pulmonary embolism, were included in the group.
- Suffer from severe mental illness or serious diseases that affect their survival, such as AIDS.
Sites / Locations
- Yuetan Community Health Service Center Fu Xing Hospital, Capital Medical UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
Intervention group
Control group
Arm Description
The standardized anticoagulation management program of atrial fibrillation in primary medical institutions was implemented for the patients with atrial fibrillation in the intervention group.
The current general practitioner management mode was continued for the patients with atrial fibrillation in the control group.
Outcomes
Primary Outcome Measures
Anticoagulant treatment rate, %
Anticoagulant therapy rate (%) = number of people actually receiving anticoagulant therapy / number of people who should receive anticoagulant therapy x 100%anticoagulant therapy / the total number of people who should receive anticoagulant therapy x 100%.
Incidence of bleeding and thromboembolic events
Incidence of thromboembolic events / anticoagulation related bleeding events (%) = number of thromboembolic events / anticoagulation related bleeding events in a certain period / number of people observed in the same period x 100% (unit: person year)
INR compliance rate
INR compliance rate (%) = the number of INR compliance (2.0 / 3.0) / the total number of INR monitored in the same period × 100%
Secondary Outcome Measures
Anticoagulant compliance rate
Using the Chinese revised version of Morisky Drug Compliance scale
Knowledge awareness rate of atrial fibrillation
Awareness rate = the number of correct questions answered by the respondents / the total number of questions answered by the respondents x 100%.
Full Information
NCT ID
NCT05316870
First Posted
January 25, 2022
Last Updated
April 6, 2022
Sponsor
Beijing Municipal Health Commission
Collaborators
Exhibition Road Community Health Service Center of Xicheng District, Beijing, China, Xinjiekou Community Health Service Center of Xicheng District, Beijing, China, Guanwai Community Health Service Center of Xicheng District, Beijing, China, Guannei Community Health Service Center of Xicheng District, Beijing, China
1. Study Identification
Unique Protocol Identification Number
NCT05316870
Brief Title
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
Acronym
AMS-AF
Official Title
Construction and Evaluation of Standardized Anticoagulant Management Model of Atrial Fibrillation in Primary Medical Institutions Under Hierarchical Diagnosis and Treatment System
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 4, 2020 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Beijing Municipal Health Commission
Collaborators
Exhibition Road Community Health Service Center of Xicheng District, Beijing, China, Xinjiekou Community Health Service Center of Xicheng District, Beijing, China, Guanwai Community Health Service Center of Xicheng District, Beijing, China, Guannei Community Health Service Center of Xicheng District, Beijing, China
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Study types and hypotheses: multicenter randomized controlled trials. This study predicts that standardized anticoagulation management of atrial fibrillation in primary health care institutions can reduce the prevalence of atrial fibrillation stroke by 50%.
Formulation and revision of standardized anticoagulation management plan and process for atrial fibrillation in primary health care institutions.
Using the mature anticoagulation management model of atrial fibrillation for reference, based on the clinical data and disease management needs of patients with atrial fibrillation in five community health service centers in Xicheng District of Beijing. To formulate the anticoagulation management plan and process of atrial fibrillation suitable for grass-roots medical institutions. After the completion of the first draft of anticoagulation management plan and process, two rounds of multi-disciplinary experts were organized to demonstrate the feasibility and scientific nature of the first draft. Finally, based on the practice and effect evaluation of clinical application management, the scheme is revised and improved.
To evaluate the feasibility and clinical application effect of standardized anticoagulation management scheme and process for atrial fibrillation.
First of all, the baseline clinical database of patients with multicenter atrial fibrillation was established; secondly, patients with atrial fibrillation who met the entry criteria were randomly included in the trial group or control group and followed up for two years. The anticoagulation treatment rate, the incidence of bleeding and thromboembolic events, anticoagulation compliance rate and knowledge awareness rate of atrial fibrillation in the two groups were compared, and the effect of standardized anticoagulation management of atrial fibrillation in primary medical institutions was evaluated.
Detailed Description
To organize experts to formulate a standardized anticoagulation management plan and process for atrial fibrillation in grass-roots medical institutions
Write the first draft of "standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions" By searching the anticoagulation management guidelines and expert consensus of atrial fibrillation at home and abroad, do a comparative study, determine the main points of anticoagulation management; analyzing the baseline clinical database of patients with multicenter atrial fibrillation, combined with quantitative and qualitative research, to explore the anticoagulation management needs of patients with atrial fibrillation. Based on the above results, the first draft of standardized anticoagulation management plan and process of atrial fibrillation in grass-roots medical institutions was written.
Organize expert group interviews. A multidisciplinary expert group was identified, including cardiology, neurology, general medicine, nursing and pharmacy, with 1 or 2 middle-level and above professionals selected in each discipline. Design the interview outline, according to the interview outline, a senior general practitioner encourages and guides the team members to express their own views on the subject. The main contents include: how scientific is this anticoagulation management scheme? What is the value of clinical application? What are the difficulties in the implementation process? What are the contents that need to be further improved?
Revision and improvement of "standardized anticoagulation management scheme and process for atrial fibrillation in primary medical institutions" According to the results of the expert group interview, revise and further improve the "standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions" to generate the final intervention plan.
To evaluate the clinical effect of standardized anticoagulation management scheme and process for atrial fibrillation.
Observation indicators Main outcome measures: the rate of anticoagulant therapy, the rate of reaching the standard of INR, the incidence of bleeding and thromboembolic events at 3 months, 6 months, 9 months, 12 months, 18 months and 24 months.
Secondary indicators: anticoagulant compliance rate and knowledge awareness rate of atrial fibrillation at 6 months, 12 months and 18 months. Blood routine: hemoglobin, platelet; biochemistry: glutamic pyruvic transaminase, glutamic oxaloacetic transaminase, serum creatinine, urea nitrogen, glomerular filtration rate; electrocardiogram / dynamic electrocardiogram, echocardiography.
Follow-up plan Patients' symptoms and signs, diet and exercise in the process of anticoagulation management were followed up once a month, and when unmanageable new symptoms or drug side effects appeared, they were referred to secondary or tertiary hospitals for treatment in time; a regular comprehensive physical examination was arranged once a year, including blood routine, biochemical, ECG / dynamic electrocardiogram, echocardiography, etc., and the follow-up period was 2 years.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation
Keywords
Atrial fibrillation, Anticoagulation management plan and process, Primary medical institutions
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Each community health service center randomly included patients with atrial fibrillation who met the admission criteria into the trial group or the control group. The intervention measures are the standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions.
Masking
Participant
Masking Description
Single Blind
Allocation
Randomized
Enrollment
380 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention group
Arm Type
Experimental
Arm Description
The standardized anticoagulation management program of atrial fibrillation in primary medical institutions was implemented for the patients with atrial fibrillation in the intervention group.
Arm Title
Control group
Arm Type
Other
Arm Description
The current general practitioner management mode was continued for the patients with atrial fibrillation in the control group.
Intervention Type
Behavioral
Intervention Name(s)
Standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions
Intervention Description
Compared with the current anticoagulation management service, we pay more attention to early initiation of anticoagulant therapy and long-term follow-up management.
Intervention Type
Behavioral
Intervention Name(s)
Conventional general practitioner management model
Intervention Description
The current general practitioner anticoagulation management model was continued in the control group.
Primary Outcome Measure Information:
Title
Anticoagulant treatment rate, %
Description
Anticoagulant therapy rate (%) = number of people actually receiving anticoagulant therapy / number of people who should receive anticoagulant therapy x 100%anticoagulant therapy / the total number of people who should receive anticoagulant therapy x 100%.
Time Frame
Change from Baseline Anticoagulant treatment rate at 24 months
Title
Incidence of bleeding and thromboembolic events
Description
Incidence of thromboembolic events / anticoagulation related bleeding events (%) = number of thromboembolic events / anticoagulation related bleeding events in a certain period / number of people observed in the same period x 100% (unit: person year)
Time Frame
Change from Baseline bleeding and thromboembolic events rate at 24 months
Title
INR compliance rate
Description
INR compliance rate (%) = the number of INR compliance (2.0 / 3.0) / the total number of INR monitored in the same period × 100%
Time Frame
Change from 12 months INR compliance rate at 24 months
Secondary Outcome Measure Information:
Title
Anticoagulant compliance rate
Description
Using the Chinese revised version of Morisky Drug Compliance scale
Time Frame
Change from 12 months INR compliance rate at 24 months
Title
Knowledge awareness rate of atrial fibrillation
Description
Awareness rate = the number of correct questions answered by the respondents / the total number of questions answered by the respondents x 100%.
Time Frame
Change from 12 months INR compliance rate at 24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years old, regardless of sex.
It is consistent with the diagnostic basis of atrial fibrillation in "Atrial Fibrillation: current Cognition and treatment recommendations-2018".
Receive oral anticoagulant therapy, such as warfarin or NOACs, as needed.
There is a contracted family doctor (if not, they can be included in the study after guiding them to sign up for a family doctor).
Have certain reading comprehension ability, be able to follow up regularly, have good compliance, and select the residents living in the vicinity.
Volunteer to participate in this clinical study and sign a written informed consent form
Exclusion Criteria:
Other diseases requiring anticoagulant therapy, such as pulmonary embolism, were included in the group.
Suffer from severe mental illness or serious diseases that affect their survival, such as AIDS.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
lan Ding, Bachelor
Phone
0086-13621031422
Ext
0086-68056002
Email
ytzxkyb@126.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xia J Wang, Master
Organizational Affiliation
FuXing Hospital, Capital Medical University
Official's Role
Study Chair
Facility Information:
Facility Name
Yuetan Community Health Service Center Fu Xing Hospital, Capital Medical University
City
Beijing
State/Province
Beijing
ZIP/Postal Code
0086
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
xia J Wang, Master
Phone
0086-18800159266
Ext
0086-68017528
Email
1457200352@qq.com
12. IPD Sharing Statement
Learn more about this trial
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
We'll reach out to this number within 24 hrs